ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507
16 June 2009 - 4:42AM
PR Newswire (US)
PHILADELPHIA, June 15 /PRNewswire/ -- ERT (NASDAQ:ERES), a leading
provider of centralized ECG and eClinical technology, ePRO, and
other services to the biopharmaceutical, medical device, and
related industries, announced today that it will be showcasing its
portfolio of products and services at Booth #507 at the 45th Annual
DIA Meeting, 21-25 June 2009 in San Diego, CA. ERT will be
showcasing, for the first time since its successful Company
rebranding exercise, its four new sub-brands of its
industry-leading products and services, including ERT ePRO
Solutions, ERT Cardiac Safety Solutions, ERT EDC Solutions, and ERT
Clinical Research Consulting Group. ERT representatives will be at
the ERT booth at the DIA Annual Meeting to discuss the Company's
latest innovations, as well as the latest advancements within the
industry. ERT is also inviting delegates to attend a presentation
from its partner, Healthcare Technology Systems (HTS) Inc., which
will be held on Wednesday, June 24, 3.30pm-5.00pm. The presentation
entitled "Addressing Suicidality in Clinical Trials" will be
chaired by John H. Greist, MD of HTS Inc and will discuss FDA
safety concerns and regulatory requirements regarding suicidality
assessments and the Columbia Suicide Severity Rating Scale (C-SSRS)
and Columbia Classification Algorithm of Suicide Assessment
(C-CASA). Delegates will be able to learn about computer-automated
suicidality assessment options, as well as learn about methods and
techniques for follow-up with patients. For further information or
to register for this presentation, please visit
http://www.ert.com/ePRO. The DIA Annual Meeting is the
biopharmaceutical industry's largest global event, drawing over
5,000 industry professionals each year and over 450 exhibiting
companies from all over the world. Additionally, DIA Annual
features over 400 conference sessions including key speakers from
key regulatory agencies, e.g. FDA and EMEA. ERT is a leading
provider of technology and services to the biopharmaceutical and
medical device industries around the world. The four key areas of
ERT products and services are all enabled by the Company's
innovative technology platform -- EXPERT(TM). EXPERT(TM) is a
robust, secure, and validated clinical-research workflow-processing
system that powers centralized electronic data collection, data
management, and information exchange. For further information about
ERT's clinical trial solutions please visit Booth # 507 at DIA 45th
Annual Meeting. Alternatively, email , call +1 215 972 0420 or
visit http://www.ert.com/. For further press information, contact
Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road,
Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477
539539, Fax +44 1477 539540, Email ERT Based in Philadelphia, PA,
ERT (eResearchTechnology, Inc.) (www.ert.com) is a provider of
technology and services to the global biopharmaceutical and medical
device industries. The Company is the market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The Company also provides technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements,
including, but not limited to, 2009 financial guidance, involve a
number of risks and uncertainties such as the Company's ability to
obtain new contracts and accurately estimate net revenues due to
uncertain regulatory guidance, variability in size, scope and
duration of projects, and internal issues at the sponsoring client,
integration of acquisitions, competitive factors, technological
development, and market demand. As a result, actual results may
differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the
Company's financial results can be found in the Company's Reports
on Form 10-K and 10-Q filed with the Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events, or otherwise. DATASOURCE: ERT CONTACT:
Fiona Robinson of The Scott Partnership, +44-1477-539539, ; or John
Blakeley of ERT, +1-215-972-0420, Web Site: http://www.ert.com/
Copyright